March 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Jul 13, 2025, 17:57

Preventing VTE in Cancer, Maintaining Low Bleeding Risk: Reduced-Dose Apixaban

Mario Balsa, medical oncology resident at Institut Català d’Oncologia, shared an insightful post on X:

” ‘New’ The New England Journal of Medicine (NEJM) study in 1,766 patients with cancer-associated VTE:

Reduced-dose apixaban (2.5mg BID) vs full dose (5mg BID)
VTE recurrence: 2.1% vs 2.8%
Clinically relevant bleeding: 12.1% vs 15.6%

Same protection, less bleeding. Sometimes, less really is more!”

Effects of reduced dose of an oral anticoagulant on thromboembolic events and bleeding are discussed in the new study ”Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism” published by Isabelle Mahé et al. in the New England Journal of Medicine (NEJM).

In patients with active cancer and venous thromboembolism, extended treatment with reduced-dose apixaban was as effective as the full dose in preventing recurrent events.

Moreover, dose reduction resulted in fewer bleeding complications.

This supports reduced-dose apixaban as a safer alternative for long-term anticoagulation in this population.

Never miss the scientific advancements in the World of Hematology, read Hemostasis Today.